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The dynamic crosstalk between the heterogeneous sub-populations of breast cancer cells, 
immune cells and their complex interactions with the tumour microenvironment confer 
significant plasticity to breast cancer. This is largely responsible for the difficulty in 
understanding the mechanisms by which tumour initiation, progression, metastasis and 
treatment failure occurs. Although our understanding of breast cancers has generally increased 
over the past decades owing to advancement of several molecular and genetic techniques, the 
disease remains puzzling due to several vital gaps in knowledge.  
To explain how tumour initiation and progression occurs, several models have been proposed 
including the clonal evolution theory1,2  and the genetic alteration theory23. While the former 
postulates mutations in a single or few cells leading to uncontrolled and unlimited proliferation 
of cells, the latter proposes the significant accumulation of genetic alterations leading to either 
gain or loss in function mutations of proto-oncogenes and tumour suppressor genes 
respectively1-3.  This is responsible for the characteristic hallmarks of cancer4,5. It has also been 
shown that several subpopulations of cells in different stages of the cell life cycle exist in breast 
cancer6,7.  Several models have been propounded as well in an attempt explain the cellular 
heterogeneity of breast carcinoma but none currently explain this inherent complexity7-9. 
Prominent among them are the hierarchical and the stochastic models9.  The evidence of a few 
cells with stem like properties having the propensity to self-renew and also differentiate into 
mature non-stem cell cancer progenies in the tumour gives support to proponents of the 
hierarchical stem cell theory8,10. According to this model, cellular heterogeneity within a 
tumour result from the presence or absence of different cells in varying levels of the cell cycle 
possessing tumour initiation potential. These cells are referred to as cancer stem cells10. This 
model proves to be an elaboration of the oversimplified clonal evolution theory.   The stochastic 
model however proposes the resulting effect of immune and environmental remodelling 
together with the intrinsic gene regulatory signals as being responsible for the different tumour 
sub-populations and not the variation in tumour initiating potential11,12. Owing to the inability 
of these models to adequately explain the heterogeneity of breast cancer, further research is 
required. Research into understanding the heterogeneity of breast cancer, on the disease 
initiation, progression, metastasis and how it confers poor outcomes has led to a relatively new 




Cancer Stem Cells (CSC) 
Several studies have referred to CSC with diverse terminologies including stem-like cancer 
cell, tumour-initiating cell, tumourigenic cell, side population cell, and clonogenic stem-like 
cell. Although CSC are a minor subset of the tumour subpopulations, their importance in the 
tumour microenvironment is however very crucial13.  Since these cells have the properties of 
self-renewal, proliferation and differentiation, they are found at the crossroads of important 
tumour events such as tumour initiation and progression. CSC having significant mutational 
events can initiate tumourigenesis and produce clone for tumour progression. They can also 
differentiate into other tumour sub-populations increasing the tumour heterogeneity.   CSC are 
notorious for entering quiescence thereby evading therapeutic agents aimed at targeting rapidly 
proliferating cells leading to relapse and treatment failure14-16. Among the putative CSC 
markers are CD44+/CD24+/low, Aldehyde dehydrogenase 1 (ALDH1), BMI1, and CD133. 
  
CD44+/CD24-/low 
One of the most well studied putative stem cell markers for breast cancer is the transmembrane 
glycoprotein CD44. It is linked with aggressive behaviour in breast cancer in several studies17-
19. The involvement of CD44 in tumourigenesis, proliferation, cellular adhesion, motility and 
metastases has been identified18-20. The high expression of this glycoprotein coupled with the 
absence or low expression of the glycosylated mucin-type protein CD24 are expressed in a 
number of haematological and other solid malignancies19-21. The role of the CD44+/CD24-/low 
phenotype as a CSC marker in breast cancer remains largely puzzling and is under intense 
investigation. While some earlier works significantly associate this phenotype with poor breast 
cancer prognosis such as shorter recurrence free and overall survival22-26, others however report 
the contrary27,28. According to Al hajj and colleagues, CD44+/CD24-/low cells have tumour 
initiating potential and became successful tumour xenografts when transferred into the 
mammary fat pads of immunodeficient mice17.  A study in primary breast tumours after 
radiation and chemotherapy, CD44+/CD24−/low cells demonstrate intrinsic resistance to 
chemotherapy29.  It is of critical essence that that additional studies focus on the expression of 





Aldehyde Dehydrogenase 1 (ALDH1) 
Aldehyde dehydrogenase 1 (ALDH1) has also emerged a well-recognised CSC marker.  
ALDH1 is a detoxifying enzyme responsible for the oxidation of intracellular aldehydes. 
Several studies on ALDH1 in breast cancer have indicated its association with poor prognosis30-
34. ALDH1 expression in breast cancer ranges from as low as 8.4% to as high as 95%35-38 with 
the wide range attributable to sample selection and varied cut off points employed by various 
investigators34. The addition of ALDH1 has greatly enriched tumourigenic capacity of 
CD44+/CD24-/low as evidence suggests associations between the CD44+/CD24-/low / ALDH1+ 
phenotype and basal –like phenotype, high histologic grade and poor prognosis in breast 
cancer24.  One in vitro study identified this combined phenotype as having the strongest ability 
of self-renewal, invasion, proliferation and tumourigenicity39. CD44+/CD24-/low/ALDH1+ 
phenotype is thought to be more reliable in characterising BCSC than individual phenotypes40.    
The importance of CD44+/CD24-/low/ALDH1high in chemotherapy and radiation resistance has 
also been elucidated in recent studies suggesting a crucial role of ALDH1 in treatment 
response41. ALDH+ cells show a more hybrid Epidermal Mesenchymal morphology with different 
spatiotemporal localisation compared to the more mesenchymal like CD44+/CD24-. ALDH+ cells are 
more centrally localised towards the stromal part of the tumour while CD44+/CD24- cells are 
distributed around the invasive end of the tumours42.  
 
 CD133 (Prominin-1) 
The Cluster of Differentiation 133 (CD133) otherwise known as Prominin-1 (PROM1) has recently 
been identified as a specific CSC marker 43-47. A constellation of studies has identified its overexpression 
in several solid cancers including brain, prostate, colon, hepatocellular, ovarian, colon and lung 
contributing to adverse clinical outcomes including shorter survival, tumour progression and recurrence 
48-51. Prominin-1 is a pentaspan transmembrane glycoprotein located in membrane appendages such as 
microvilli and in the apical surface of some epithelial cells52. It plays a crucial role in stem cell migration 
and asymmetric division53. PROM1 gene is located on chromosome 4 in humans with a 60% homology 
with that located on chromosome 5 in mice54 and has been identified as an important CSC marker in 
triple negative breast cancers52,55,56.  In vitro studies of CD133+  in BRCA1 associated breast cancer cell 
lines  have  identified characteristics including the ability to form spheroids, expression of stem cell 
genes and higher proliferative output, as well as the ability to reconstitute tumours with as few as 100 
cells in in vivo studies57. Also, BRCA1 breast tumours with the CD44+CD24-/low CSC marker 
characteristics has is an association with CD13355.  In triple negative breast tumours, CD133 is 
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associated vasculogenic mimicry known to significantly impact tumour relapse 52,57,58.  This gives a 
strong indication that its expression could help in prognostication and determination of appropriate 
treatment58,59.  
 
B cell	specific Moloney murine leukemia virus integration site 1 (BMI1) 
B cell	specific Moloney murine leukemia virus integration site 1 (BMI1) is transcriptional repressor of 
the Polycomb group (PcG) of transcription factors. The gene is located on the short arm of chromosome 
10. BMI1 gene comprises of 10 exons and 9 introns encoding a 326 amino acids protein of 
approximately 36.8kDa60. The N terminal end of BMI1 protein contains a conserved ring finger domain 
and a central helix-turn-helix-turn helix-turn motif (H-T-H-T) notable for inducing telomerase 
activity61,62. The nuclear localisation signals of BMI1; KRRR and KRMK are conserved with high 
expression in a variety of tissues including brain, thymus, kidney, lungs, blood and bone marrow.  
BMI1 has been linked with several cancers with properties of self-renewal, proliferation, Epithelial and 
Mesenchymal Transition, and chemoresistance60,63. Evidence also exist in BMI1 acting as an epigenetic 
modifier protein involved in the maintenance of CSCs64,65. Via the activation of telomerase, BMI1 also 
inhibits cellular senescence, evade apoptosis to increase cell longevity60,66. This phenomenon plays a 
key CSC property in chemoresistance.   The expression of BMI1 has mainly been characterised in 
haematopoietic malignancies67-69 but other solid tumours such as lung, prostate, liver, medulloblastoma, 
neuroblastoma, colon and nasopharyngeal carcinomas have also been identified70-76.  
The role of BMI1 in mammary carcinogenesis has been established in a number of studies and currently 
under intense research31,77,78. While some studies conclude an association with favourable prognosis79-
81, others report the contrary67,82. According to Arnes et al, there was no association between BMI1 
positivity and basal like features and low Ki67 expression in breast carcinoma79. BMI1 expression has 
also been associated with relapse free survival and overall survival in univariate analysis81. Same study 
also concluded BMI1 expression as an independent prognostic for overall survival especially in ER 
positive breast cancer81. Conversely,  in a univariate and multivariate analysis conducted, Kim et al 
concluded that BMI1 may be involved in tumour progression and metastasis since its overexpression 
correlated with axillary lymph node metastasis and positive estrogen receptor status80. The high 
expression of BMI1 has also been found to correlate with markers of poor clinical outcomes such as 
high expression p53 and the absence of progesterone receptor. With such conflicting evidences in the 
role of BMI1 in breast cancer, further research is warranted to further throw more light on the role of 
BMI1 in breast cancer.   
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The role of BMI1 varies in different cancer types. The overexpression of BMI1 plays a vital role in self-
renewal, cancer cell proliferation, invasion/metastasis, chemoresistance and survival. The self-renewal 
CSC regulatory role is encountered in type 1 neuroblastoma through an expression dependent specific 
lineage commitment83. In neuroblastoma, BMI1 knockdown in progenitor cells suppressed proliferation 
and disease development84. BMI1 expressing leukaemia Stem Cells induced leukaemia in irradiated 
mice whereas cells lacking BMI1 expression did not85. Clinical outcomes of patients who received 
adjuvant therapy in Non-Small Cell Lung Cancer (NSCLC) were better in BMI1 negative tumours 
compared to BMI1 positive tumours60. In Hepatocellular carcinoma, low expression of BMI1 correlates 
with reduction of tumour invasiveness86. A high expression of BMI1 in gastric cancer enhanced tumour 
migration and invasiveness87. The role of BMI1 in inducing Epithelial-Mesenchymal Transition is 
revealed in endometrial carcinoma88. BMI1 overexpression is associated with insensitivity to 
conventional chemotherapy and radiotherapy. This has been well documented in haematological 
malignancies and breast malignancies77,85,89,90.   
 
 
Table 1: The role of cancer stem cells in different types of cancers 
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Clinicopathological significance of Cancer Stem Cells 
Prognostication 
The identification of CSC in tumours offer important evidence on tumourigenesis, tumour 
progression, metastasis, therapeutic resistance and recurrence. These may serve as important 
targets for diagnostic and targeted therapies. Prognostication of patients may also be based on 
presence or absence of specific CSC in tumours.  Earlier researchers have focused on 
elucidating the association that exist between CSC, prognostic markers and response to 
adjuvant therapy. Basal like phenotype (BLP) in breast cancer with basal cell markers having 
poor prognosis are associated with candidate CSC markers CD44+/CD24-24,31,103,104 . This 
phenotype has also been implicated in malignant relapse following conventional therapies105. 
Although there are a few conflicting results, ALDH1 expression is generally associated with 
Nasopharyngeal carcinoma 101 
 EMT 
Endometrial Ca 





poor clinical outcome and resistance to chemotherapy due to its high expression in Triple 
Negative Breast Cancer (TNBC)32.  
 
Tumourigenicity of Cancer Stem Cells 
It is evident that different breast CSC have different levels of tumourigenic potential. Greater 
tumourigenicity has been realised in tumours expressing multiple breast CSC markers. For 
instance, a high tumourigenic capacity is realised in tumours expressing combined 
CD44+/CD24-/low/ALDH1+ when compared with tumours without either of these markers 
according to Da Cruz et al. The high tumourigenicity of this CSC phenotype is evident by the 
ability to form tumours from as low as 20 cells106. Another in vitro study also identified this 
combined phenotype as having the strongest ability of self-renewal, invasion, proliferation and 
tumourigenicity39. Although there has been some significant correlation of some breast CSC 
with clinicopathological features there are those that have shown otherwise104.   Conflicting 
associations are similarly observed with respect to BMI1 in other studies31. These studies have 
put CSC in the spotlight not only in breast cancer but in other haematological and non-
haematological cancers as well107. It is imperative that additional studies into the correlation of 
CSC between clinicopathological features and clinical outcomes are conducted to expatiate 
their tumourigenic potential.   
 
Cancer Stem Cells and treatment failure/relapse 
Treatment failure and tumour recurrence remains a major challenge in breast cancer therapy. 
In recent years, chemoresistance has strongly been linked to some candidate stem cells through 
a number of mechanisms. Among these include ABC transporter expression which actively 
pump-out chemotherapeutic compounds from tumour cells. By extrusion of the agent, the 
tumour evades the therapeutic action. The enzyme Aldehyde dehydrogenase1 ALDH1 converts 
aldehydes into carboxylic acids through oxidation. It is an important mechanism by which CSC 
cause treatment failure. B-cell lymphoma-2 (BCL2) related chemoresistance also impairs the 
ability of affected cells to release proapoptotic proteins such as cytochrome C enhancing cell 
immortalisation108. Others include enhanced DNA damage response and activation of key 
signalling pathways. Another property of CSC is their ability to enter a state of dormancy 
evading chemotherapeutic agents aimed at actively proliferating cells9. Knowledge into the 
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chemoresistance properties of CSCs is valuable in overcoming the challenges inherent in most 
breast cancer treatment modalities to improve clinical outcomes for patients. The ability of 
cancer regimens to target quiescent CSC and eliminate these cells from the tumour is 
paramount in overcoming treatment failure and tumour recurrence.   
Compelling evidence in CSC in the past few decades have given clear indication that 
therapeutically targeting CSC in combination with traditional chemotherapy and radiotherapy 
has the potential of making cancer therapy more potent109,110. The potential for the therapeutic 
use of CSC is now made unequivocal through the inhibition of CSC function, CSC eradication, 
reversal of resistance and induction of CSC differentiation. This relatively new cancer research 
niche has the great promise of unearthing more cancer therapeutic regimen and to potentiate 
the effectiveness of conventional treatments directed against tumour bulk.  
 
Racial Heterogeneity and Cancer Stem Cells 
Although research evidence on CSC is currently being conducted in Caucasian breast cancer 
populations, studies in African populations remain significantly low.  Compared to their 
Caucasian counterparts, breast cancers of African origin are relatively aggressive111-113. A 
plethora of research has given evidence of increased triple negative breast cancer and breast 
CSC in Africans and people of African ancestry31,32,114.   The aggressiveness of breast tumours 
of African origin, the late reporting stage, the high therapeutic resistance, increased 
recurrences, increasing morbidity and mortality and poor overall survival compounded by 
prevailing poor socio-economic indicators such as poverty, and lack of knowledge have made 
breast cancer treatment challenging in Africa. This underscores the need for intensified 
molecular research to understand the peculiarities of the clinicopathological phenotype in 
relation to the profile of CSC of tumours in African population. This will help in the 
development of novel therapeutic strategies to target these aggressive cancers and to decrease 
morbidity and mortality in Africans. 
There is well-documented evidence of racial difference of cancer risk, prevalence and clinical 
outcome115-117. Although there is complex racial heterogeneity, an interesting trend of 
increasing poor outcomes appears to exist with increasing level of African ancestry116,118. 
Though African-Americans have lower risk of breast cancer compared with Caucasians, 
African-Americans have significantly higher cancer related deaths in the USA117. This 
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population also record higher prevalence of ER-negative, TNBC and early onset breast 
cancer115,119,120.   
Since the tumourigenicity of BCSC was first demonstrated by Alhaji et al in 2003, population 
based comparative ethnic and racial studies comparing the expression pattern of BCSC in 
different ethnic groups and races remain scanty. Therefore, a study comparing the breast CSC 
profile in Caucasians, Western sub-Saharan African descents, native Africans is plausible. Here 
we review Breast CSC studies in African Populations and elucidate their differences with races.   
A study in Uganda revealed a high prevalence (48%) of ALDH1 associated with aggressive 
tumours (TNBC and HER2) in 192 breast cancer cases31. Similar studies conducted in Ghana 
also reported  comparable findings of 42%32 and 45%33 ALDH1 expression in 104 and 147 
breast carcinoma patients respectively. Conversely, less than 30% of ALDH1 expression is 
reported in a number of European and White American tumours114.  In all studies, ALDH1 was 
significantly associated with TNBC.  In Asian populations, a range of 40% to 65% ALDH1 
positivity is found all of which were associated with poor prognosis comparable to their African 
counterparts121-126. Similarly, a high tumour grade was associated with ALDH1 positivity121,122. 
Conflicting reports have however characterised ALDH1 expression metastasis to axillary 
lymph nodes123-125 and tumour size30,124. ALDH1 is associated with poor clinical outcomes 
such as shorter relapse free survival and overall survival122,123.  None of the African studies 
however associated ALDH1 with clinical outcome. There has not been any report of 
CD44+/CD24-/low / ALDH1+ CSC phenotype study in an African cohort.   
In a study which compared African-American and Hispanic/Latina, women with a high 
CD44+/CD24-/low expression was reported in TNBC in both populations127. The increased 
incidence of CD44+/CD24-/low was associated significantly with disease free survival in 
univariate analysis but was however not an independent predictor when subjected to a 
multivariate analysis127. A plethora of studies have compared racial and ethnic disparities in 
cancer, but non comparing CSC in African populations.       
Most CSC studies conducted in African populations focused only on ALDH1 except for 
Nalwoga et al31. None of these studies have therefore elucidated the relationship between 
ALDH1 and other stem cell markers such as CD44+/CD24-/low, BMI1, and CD133.  While 
ALDH1 is associated with poor prognosis, a meta-analytical studies by Zhou et al128, Li et al 
40  suggest a combination of CD44+ CD24-/low and ALDH1 as a better CSC buttressing the 
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assertion that ALDH1 activity does not universally select for the most clonogenic cells in 
certain breast cancer cell lines41.  
 
CONCLUSION 
Breast cancer heterogeneity is evidenced by various histological subtypes, with variable 
clinical presentations and diverse molecular signatures. The use of a single biomarker as CSC 
marker is not adequate. It is therefore imperative that additional research focuses on 
combinations of biomarkers that can reliably select BCSC phenotypes.  
Most African studies have not yet associated CSC with clinical outcomes such as resistance to 
chemotherapy, and overall survival. Breast cancer patients in Africa usually present with higher 
stage and grade and mostly require neo-adjuvant chemotherapy to downstage the tumour before 
surgery and subsequent therapy. It is important that studies into the significance of CSC before 
and after neo-adjuvant therapy and correlated with prognostic parameters and clinical outcomes 
are conducted. Studies into the clinicopathological significance of other recognised BCSC 
markers such as CD133, and BMI1 remain a fallow research area in African populations.  Long 
term follow-up studies are strongly recommended in African cohorts to identify the relationship 
between these breast cancer stem cell markers, prognosis and clinical outcomes. The 
relationship between various histological subtypes and the various BCSC is similarly not well 
established in African cohorts. A study comparing Invasive Ductal Carcinoma-NOS with 
Invasive Ductal Carcinoma-SHT is also yet to be conducted in an African population.   
Although poor socioeconomic status remains a significant risk factor for poor breast cancer 
outcomes in African populations129,130, it does not exhaustively explain why breast cancers of 
Africans and those of African ancestry are aggressive and exhibit such adverse clinical 
outcomes. Underlying molecular and genetic signatures are of great importance, particularly 
the significance of CSC in contributing to such disparity between Africans and other races. 
Several studies are currently underway to explain this observation.  Comparing CSC in racial 
and ethnic population studies is of outmost importance in the identification the similarities and 
differences that exist among races to enable the development of effective personalised 
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